Effective combination chemo/hormonal therapy for malignant melanoma: Experience with three consecutive trials

International Journal of Cancer

Volumn 50, Issue 4, 1992, Pages 553-556

  McCiay, Edward F ^a   Mastrangelo, Michael J ^b   Berd, David ^b   Bellet, Robert E ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARMUSTINE; CISPLATIN; DACARBAZINE; TAMOXIFEN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; FEMALE; HORMONAL THERAPY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MELANOMA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SURVIVAL;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; HUMAN; MELANOMA; MIDDLE AGE; NEOPLASM METASTASIS; SUPPORT, NON-U.S. GOV'T; TAMOXIFEN;

EID: 0026551390     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.2910500410     Document Type: Article

References (27)

1. Tamoxifen versus ethinyl estradiol in the treatment of post‐menopausal women with advanced breast cancer
2. DTIC vs. DTIC plus tamoxifen in metastatic malignant melanoma
3. DTIC vs. DTIC plus tamoxifen in metastatic malignant melanoma
4. Lomustine, bleomycin and cisplatin in patients with metastatic melanoma
5. Therapy of malignant melanoma with an imidazole carboximide and bis‐chloroethyl nitrosourea
6. Combination chemotherapy with cuplatin, carmustine, dacabarzine and tamoxifen in metastatic melanoma
7. Cancer procoagulant in human tumor cells. Evidence from melanoma patients
8. Tamoxifen treatment of metastatic cancer and anti‐thrombin III levels
9. Combination chemotherapy in disseminated melanoma and Other solid tumors in adults
10. Melphalan‐induced DNA cross‐linking in human melanoma cells and phytohaemagglutinin‐stimulated lymphocytes in relation to intracellular drug content and cellular levels of glutathione
11. Enhancement of the anti‐proliferative effect of cis‐diamminedichloroplatinum (II) and nitrogen mustard by inhibitors of protein kinase C
12. Chemotherapy by fotemustine in cerebral metastases of disseminated malignant melanoma
13. Steroid hormone receptors and tamoxifen treatment in malignant melanoma
14. Tamoxifen is a calmodulin antagonist in the activation of cAMP phosphodiesterose
15. Phase II trial of tamoxifen in malignant melanoma
16. Increased mdr gene expression and decreased drug accumulation in multidrug‐resistant human melanoma cells
17. Venous thrombosis as a side effect of tamoxifen treatment
18. Modulation of cisplatin accumulation by forskolin in human ovarian carcinoma cells
19. Tamoxifen in the treatment of malignant melanoma
20. Cutaneous melanoma
21. Combination chemotherapy and hormonal therapy in the treatment of malignant melanoma
22. The importance of tamoxifen to a cisplatin‐containing regimen in the treatment of metastatic melanoma
23. Treatment of metastatic melanoma with dacarbazine and cisplatin
24. High‐dose tamoxifen in metastatic melanoma
25. Reversal of acquired resistance to doxorubicin in P388 murine leukemia cells by tamoxifen and other treparanol analogues
26. Active chemotherapy for metastatic melanoma following failure of interleukin‐2‐based therapy
27. Augmentation of procoagulant activity in monokine‐stimulated endothelial cells by calmodulin/protein‐kinase‐C inhibitors